[Statins: what is their place in the treatment of chronic kidney insufficiency?].
Dyslipidemia is highly prevalent in patients with chronic kidney disease (CKD), contributing to their high cardiovascular morbidity/ mortality risk and kidney damage. The lipid profile of patients with CKD commonly shows elevation of triglycerides, accumulation of atherogenic lipoproteins and decrease of HDL cholesterol. Statins are as safe and secure in CKD patients as in the general population. Used as secondary prevention in predialysis patients they seem to reduce cardiovascular mortality, but such beneficence has not been confirmed in dialysis patients. Data are still lacking in primary prevention. Ongoing studies may help to draw more precise recommendations. Meanwhile, we suggest starting lipid lowering drugs as secondary prevention in all patients at all stages of CKD.